Results 91 to 100 of about 8,373 (204)

Cholesterol in mRNA‐Lipid Nanoparticles can be Replaced with the Synthetic Mycobacterial Monomycoloyl Glycerol Analogue MMG‐1

Advanced Functional Materials, Volume 35, Issue 51, December 16, 2025.
This study demonstrates that cholesterol in messenger RNA‐lipid nanoparticles (mRNA‐LNPs) can be completely replaced with an immunopotentiating lipid, i.e., a synthetic analogue of the C‐type lectin receptor agonist monomycoloyl glycerol (MMG‐1), without compromising physicochemical properties, in vivo transfection efficiency, and immunogenicity of the
Abhijeet G. Lokras, Saahil S. Baghel, Rune F. Jensen, Aneesh Thakur, Henrik Franzyk, Oskar Thofte, Marco Herrera‐Barrera, Madeleine Landry, Melike Ongun, Ahmad Tami, Marlene P. Thanthrige, Eva Callens, Corinne Beinat, Thomas Rades, Søren R. Paludan, Kristian Riesbeck, Ida Rosenkrands, Dennis Christensen, Gabriel K. Pedersen, Camilla Foged   +19 more
wiley   +1 more source

Pulmonary light chain deposition disease: Case series and review of the literature

Radiology Case Reports
Pulmonary light chain deposition disease is a rare entity characterized by immunoglobulin deposition within the lung parenchyma with pathologic features distinct from pulmonary amyloidosis.
Tomas V. Gonzalez, MD, Anja C. Roden, MD, Brian J. Bartholmai, MD, Rebecca M. Lindell, MD   +3 more
doaj   +1 more source

Therapeutic Antibodies for Mosquito‐Borne Orthoflavivirus Infections: Discovery, Engineering Approaches, and Advances in mRNA‐Based Delivery Systems

Advanced Therapeutics, Volume 8, Issue 12, December 2025.
This review explores how antibody engineering and display technologies are driving therapeutic advances against mosquito‐borne orthoflaviviruses such as Zika, dengue, and yellow fever viruses. It highlights diverse neutralizing targets on the envelope protein, including the conserved fusion loop, and discusses how Fc engineering, rational antigen ...
Ana Clara Barbosa Antonelli, Lucas Silva Rodrigues, Maria Clara Moura Pinheiro, Sylvia Barbosa Pinhate, Marcelo de Macedo Brígido, Andréa Queiroz Maranhão   +5 more
wiley   +1 more source

Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis [PDF]

, 2023
Oliver Cohen, Regina Rendas‐Baum, Kristen McCausland, Darren Foard, Richa Manwani, Sriram Ravichandran, Helen J. Lachmann, Shameem Mahmood, Brendan Wisniowski, Philip N. Hawkins, Julian D. Gillmore, Kristen Hsu, Sabrina Rebello, Ashutosh Wechalekar   +13 more
openalex   +1 more source

Chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosis

, 2023
Kaini Shen, Zhuang Tian, Yajuan Gao, Yining Wang, Li Huo, Jian Li, Yun Zhang, Yuanqiang Zhang   +7 more
openalex   +1 more source

Current management of non‐amyloidosis monoclonal gammopathy of renal significance: Clinical features, treatment selections, responses and renal outcomes

British Journal of Haematology, Volume 208, Issue 1, Page 329-332, January 2026.
Daniel Cancilla, Hanny Sawaf, Xuefei Jia, Danai Dima, Ali Mehdi, Hira Shaikh, Beth Faiman, Faiz Anwer, Sandra Mazzoni, Diana Basali, Jack Khouri, Christy Samaras, Jason Valent, Shahzad Raza, Louis Williams   +14 more
wiley   +1 more source

A patient with AL amyloidosis presenting with refractory tuberculosis, chest tightness and hypotension: case report

BMC Pulmonary Medicine
Introduction Immunoglobulin light chain (AL) amyloidosis presents a clinical spectrum characterized by diverse manifestations and involvement of multiple organs, posing a significant diagnostic challenge for physicians.
Jun Yang, Mohamed Fahim Fathima Farhath, Huohuan Tian, Linhui Yang, Dan Liu   +4 more
doaj   +1 more source

Prognostic implications of clinical phenotype and severity of cardiac involvement in patients presenting with immunoglobulin light chain amyloidosis [PDF]

, 2022
Aldostefano Porcari, Ambra Masi, Adam Ioannou, Raeesa Patel, Yousuf Razvi, Lucia Venneri, Ana Martinez–Naharro, G Sinagra, Ashutosh Wechelakar, Philip N. Hawkins, JD Gillmore, Marianna Fontana   +11 more
openalex   +1 more source

野生型转甲状腺素蛋白心脏淀粉样变性病例1例

Zhongguo shiyan zhenduanxue, 2023
转甲状腺素蛋白心脏淀粉样变(transthyretin cardiac amyloidosis, ATTR-CA)是除外免疫球蛋白轻链心脏淀粉样变(immunoglobulin light chain amyloidosis, AL-CA)最常见的心脏淀粉样变(cardiac amyloidosis, CA)[1]。ATTR-CA患者生活质量差、生存率低[2]。
翟书慧, 王丹, 赵绮旎, 刘龙
doaj  

Multiple Myeloma-Associated Light Chain Amyloidosis and a Proposed Approach to Monoclonal Immunoglobulin-Associated Renal Disease [PDF]

, 2020
Zi Yun Chang, Thomas Paulraj Thamboo, Clarice Shi Hui Choong, Weng Kin Wong, Clara Lee Ying Ngoh   +4 more
openalex   +1 more source